P and T最新文献

{"title":"Newborn News.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 1","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336201/pdf/ptj4401014.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest Opioid Abuse Bill Contains Over 100 Provisions But No Far-Reaching Pharmacy Mandates.","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Will the new opioid abuse bill prove more effective than its predecessor? A plethora of provisions will have little impact on pharmacists and pharmaceuticals.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 2","pages":"29-63"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355050/pdf/ptj4402029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36953935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aligning Formulary Restrictions Across a Health System and Improving Access to and Clarity of Medication Restrictions.","authors":"Sarah Solano,&nbsp;Jordan Dow,&nbsp;Terry Audley,&nbsp;Nitish Bangalore","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>In 2013, formulary medications were aligned among the three hospitals within our health system. However, as formulary medication restrictions were not aligned, the three hospitals continued to have inconsistent medication restrictions. This led to confusion among prescribers and pharmacists about which medications were restricted, what the restrictions were, and where to access information about the restrictions. To alleviate this confusion, we set out to align formulary restrictions and to provide medication restriction details at the points of entering and verifying medication orders.</p><p><strong>Objectives: </strong>The primary objective was to align 100% of the formulary medication restrictions at our health system. The secondary objectives were to improve ease of access to restriction information and to improve the clarity of medication restrictions for pharmacists.</p><p><strong>Methods: </strong>The process of alignment involved completing a gap analysis to identify differences between each site's medication restrictions and site-specific interventions. The gap analysis, proposed restrictions, and proposed interventions were reviewed by the system's pharmacy, nutrition, and therapeutics (PNT) planning committee. The committee reviewed each medication, the restrictions, and the proposed modifications. The consensus of formulary medication restrictions was presented to the PNT committee for approval. Restriction information was added to each drug monograph in the online medication information database and the interventions were built into the electronic medical record (EMR). Five intervention types were included: restriction removal, \"outpatient use only\" added to the medication name, order-specific questions, alternative alerts, and information put into order instructions seen by both ordering providers and verifying pharmacists. Pharmacists were educated about the restricted medication-alignment initiative. A survey was administered after education to assess the ease of access to restricted medication information and clarity of medication restrictions. Because of the scope of this project, education and survey administration was limited to pharmacists only.</p><p><strong>Results: </strong>Aligned medication restrictions increased from 11% to 100%. Of the 110 medication restrictions that were not aligned, 17 restrictions were removed, 37 medications were restricted to outpatient use only, and 56 restricted medications were further aligned across the health system. Results from the survey showed that more pharmacists utilized the online medication information database to find information regarding restricted medications and that it was easier for more pharmacists to find this information.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 2","pages":"64-68"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355055/pdf/ptj4402064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36953942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosimilar Roadblock Removals Seem Tailor-Made for Trump/Democrats Agreement: Development of New Biosimilar Drugs and Marketing of Few Approved Drugs Stymied.","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The United States is lagging behind Europe in biosimilar use, and missing out on a wider range of medication options and huge savings in drug expenditures. What's causing the holdup?</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 2","pages":"45-68"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355054/pdf/ptj4402045.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36953939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Making Sure the Kids Are Alright.","authors":"Sonja Sherritze","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336203/pdf/ptj4401001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Value of Pediatricians on Pharmacy and Therapeutics Committees.","authors":"Jared P Austin,&nbsp;Sara Gunden,&nbsp;Wendy Hoffner,&nbsp;Lana Ismail,&nbsp;Suzanne Mendez,&nbsp;Francisco Alvarez","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 1","pages":"2-4"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336204/pdf/ptj4401002.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescribing Errors with Levetiracetam Oral Solution.","authors":"Matthew Grissinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Incorrectly prescribed medications can have serious implications, especially in young children. Safe practice recommendations include listing patients' age, weight, and date of birth on prescriptions, verifying discharge orders, and involving pharmacists in reconciliation.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 2","pages":"20-21"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355056/pdf/ptj4402020.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36953931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosimilars: Considerations for Payers.","authors":"James Smeeding,&nbsp;Daniel C Malone,&nbsp;Monica Ramchandani,&nbsp;Bradley Stolshek,&nbsp;Larry Green,&nbsp;Philip Schneider","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Evaluating biosimilars requires payers to go beyond cost considerations: safety and efficacy, reliability of supply and logistics, and the impact of state laws on substitution and interchangeability must all be deliberated.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 2","pages":"54-63"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355057/pdf/ptj4402054.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xofluza (Baloxavir Marboxil) for the Treatment Of Acute Uncomplicated Influenza.","authors":"Kimberly E Ng","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 1","pages":"9-11"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336199/pdf/ptj4401009.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical Approval Update.","authors":"Michele B Kaufman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Arikayce (amikacin liposome inhalation suspension) for <i>Mycobacterium avium</i> complex lung disease; Xofluza (baloxavir marboxil) for acute uncomplicated influenza; and Nuzyra (omadacycline) for community-acquired bacterial pneumonia and/or acute bacterial skin and skin structure infections.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 2","pages":"42-44"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355053/pdf/ptj4402042.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36953937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}